Literature DB >> 32464192

Neuroprotection: A versatile approach to combat glaucoma.

Santoshi Naik1, Abhijeet Pandey1, Shaila A Lewis1, Bola Sadashiva Satish Rao2, Srinivas Mutalik3.   

Abstract

In most retinal diseases, neuronal loss is the main cause of vision loss. Neuroprotection is the alteration of neurons and/or their environment to encourage the survival and function of the neurons, especially in environments that are deleterious to the neuronal health. The area of neuroprotection progresses with a therapeutically-based hope of improving vision and clinical outcomes for patients through the developments in neurotrophic therapy, antioxidative therapy, anti-excitotoxic, anti-ischemic, anti-inflammatory, and anti-apoptotic care. In this review, we summarize the various neuroprotection strategies for the treatment of glaucoma, genetics of glaucoma and the role of various nanoplatforms in the treatment of glaucoma.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Genetics; Glaucoma; Nanoplatforms; Neuroprotection

Mesh:

Substances:

Year:  2020        PMID: 32464192     DOI: 10.1016/j.ejphar.2020.173208

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  Iron Oxide Nanoparticles in Regenerative Medicine and Tissue Engineering.

Authors:  Ralf P Friedrich; Iwona Cicha; Christoph Alexiou
Journal:  Nanomaterials (Basel)       Date:  2021-09-08       Impact factor: 5.719

2.  Melatonin Prevents Non-image-Forming Visual System Alterations Induced by Experimental Glaucoma in Rats.

Authors:  María F González Fleitas; Julián Devouassoux; Marcos L Aranda; Hernán H Dieguez; Juan S Calanni; Agustina Iaquinandi; Pablo H Sande; Damián Dorfman; Ruth E Rosenstein
Journal:  Mol Neurobiol       Date:  2021-03-31       Impact factor: 5.590

3.  Presumed neuroprotective therapies prescribed by veterinary ophthalmologists for canine degenerative retinal and optic nerve diseases.

Authors:  Ryan G Hopper; Fabiano Montiani-Ferreira; Jorge da Silva Pereira; Michele C Fritz; Vickie J Ruggiero; John S Sapienza; Kumiko Kato; András M Komáromy
Journal:  Vet Ophthalmol       Date:  2021-03-07       Impact factor: 1.644

Review 4.  Looking into the future: Gene and cell therapies for glaucoma.

Authors:  András M Komáromy; Kristin L Koehl; Shin Ae Park
Journal:  Vet Ophthalmol       Date:  2021-01-07       Impact factor: 1.644

5.  Mimicking chronic glaucoma over 6 months with a single intracameral injection of dexamethasone/fibronectin-loaded PLGA microspheres.

Authors:  Alba Aragón-Navas; María J Rodrigo; David Garcia-Herranz; Teresa Martinez; Manuel Subias; Silvia Mendez; Jesús Ruberte; Judit Pampalona; Irene Bravo-Osuna; Julian Garcia-Feijoo; Luis E Pablo; Elena Garcia-Martin; Rocío Herrero-Vanrell
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 6.  Potential Therapeutic Benefit of NAD+ Supplementation for Glaucoma and Age-Related Macular Degeneration.

Authors:  Gloria Cimaglia; Marcela Votruba; James E Morgan; Helder André; Pete A Williams
Journal:  Nutrients       Date:  2020-09-19       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.